What's the most recent regulatory action in Exudative age-related macular degeneration?

Most recent: Vabysmo — FDA approved.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/exudative-age-related-macular-degeneration.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Exudative age-related macular degeneration — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exudative age-related macular degeneration (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Exudative age-related macular degeneration, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Vabysmo	FARICIMAB	Roche		Vascular endothelial growth factor A	2022-01-01
Beovu	BROLUCIZUMAB	Novartis		Vascular endothelial growth factor A	2019-01-01
Vegf Trap	AFLIBERCEPT	Regeneron	Vascular Endothelial Growth Factor Inhibitor	Vascular endothelial growth factor A	2011-01-01
Macugen	pegaptanib	Bausch Health		Vascular endothelial growth factor A	2004-01-01
Macugen	EYE001	Valeant Pharms Llc		Vascular endothelial growth factor A	2004-01-01
Visudyne	VERTEPORFIN	Bausch Lomb Ireland	Photoenhancer [EPC]		2000-01-01
VABYSMO	FARICIMAB-SVOA	GENENTECH INC		Angiopoietin-2, Vascular endothelial growth factor A
BYOOVIZ	RANIBIZUMAB-NUNA	SAMSUNG BIOEPIS CO LTD		Vascular endothelial growth factor A
Eylea	Eylea	Texas Retina Associates		Placenta growth factor, Vascular endothelial growth factor A, Vascular endothelial growth factor B
Lucentis	Lucentis	Santen Inc.		Vascular endothelial growth factor A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

2026-04-09 — Vabysmo · FDA · approved · US

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Exudative age-related macular degeneration
Bausch Health · 1 drug in Exudative age-related macular degeneration
Bausch Lomb Ireland · 1 drug in Exudative age-related macular degeneration
Bayer · 1 drug in Exudative age-related macular degeneration
GENENTECH INC · 1 drug in Exudative age-related macular degeneration
Greater Houston Retina Research · 1 drug in Exudative age-related macular degeneration
Novartis · 1 drug in Exudative age-related macular degeneration
Novartis Pharmaceuticals · 1 drug in Exudative age-related macular degeneration
Regeneron · 1 drug in Exudative age-related macular degeneration
Roche · 1 drug in Exudative age-related macular degeneration
SAMSUNG BIOEPIS CO LTD · 1 drug in Exudative age-related macular degeneration
Santen Inc. · 1 drug in Exudative age-related macular degeneration

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Exudative age-related macular degeneration:

Cite this brief

Drug Landscape (2026). Exudative age-related macular degeneration — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/exudative-age-related-macular-degeneration. Accessed 2026-06-10.

Exudative age-related macular degeneration full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing